Emerald Advisers Inc. PA Has $14,258,000 Stake in Cepheid (CPHD)
Emerald Advisers Inc. PA increased its position in Cepheid (NASDAQ:CPHD) by 4.7% during the second quarter, Holdings Channel reports. The institutional investor owned 463,671 shares of the company’s stock after buying an additional 20,803 shares during the period. Emerald Advisers Inc. PA’s holdings in Cepheid were worth $14,258,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. increased its stake in shares of Cepheid by 10.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 5,080 shares of the company’s stock valued at $156,000 after buying an additional 465 shares during the period. BlackRock Inc. increased its stake in shares of Cepheid by 77.0% in the first quarter. BlackRock Inc. now owns 4,814 shares of the company’s stock valued at $161,000 after buying an additional 2,094 shares during the period. Boston Advisors LLC increased its stake in shares of Cepheid by 0.5% in the second quarter. Boston Advisors LLC now owns 12,755 shares of the company’s stock valued at $392,000 after buying an additional 65 shares during the period. Diversified Trust Co increased its stake in shares of Cepheid by 4.8% in the second quarter. Diversified Trust Co now owns 16,250 shares of the company’s stock valued at $500,000 after buying an additional 750 shares during the period. Finally, Pacad Investment Ltd. acquired a new stake in shares of Cepheid during the first quarter valued at about $544,000. 95.32% of the stock is currently owned by hedge funds and other institutional investors.
Cepheid (NASDAQ:CPHD) traded up 0.06% during midday trading on Wednesday, reaching $52.69. 994,618 shares of the company were exchanged. The firm’s market cap is $3.85 billion. Cepheid has a one year low of $25.09 and a one year high of $53.91. The firm’s 50-day moving average is $45.58 and its 200-day moving average is $35.10.
Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.14) by $0.19. The business earned $146 million during the quarter, compared to analysts’ expectations of $145.82 million. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company posted ($0.06) earnings per share. On average, equities analysts expect that Cepheid will post $0.33 EPS for the current fiscal year.
Several analysts have issued reports on CPHD shares. Jefferies Group upped their price target on shares of Cepheid from $28.00 to $34.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Cowen and Company downgraded shares of Cepheid from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 7th. Barclays PLC upped their price target on shares of Cepheid from $36.00 to $52.00 and gave the company an “equal weight” rating in a report on Wednesday, September 7th. Morgan Stanley started coverage on shares of Cepheid in a report on Wednesday, June 15th. They issued an “equal weight” rating and a $30.00 price target on the stock. Finally, Robert W. Baird upped their price target on shares of Cepheid from $44.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, September 7th. Seventeen investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $41.83.
In related news, VP Scott A. Campbell sold 746 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $36.71, for a total transaction of $27,385.66. Following the completion of the sale, the vice president now directly owns 10,721 shares in the company, valued at $393,567.91. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.16% of the company’s stock.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Want to see what other hedge funds are holding CPHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cepheid (NASDAQ:CPHD).
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.